comprehensive -WSS

comprehensive

author：explore 2025-09-27 09:54:09 - browse：32276

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Continuity nursing helped my family in our darkest PICU moments
Next article： Eli Lilly to acquire Versanis in heated race for weight loss drugs

leisure time

WSS

Why police arrested suspected Gilgo Beach killer away from his house

The new HIV moral panic

Medicare Advantage insurers pressure Biden for bigger payments

With Wegovy coverage, Medicare patients may face high costs

Pregnancy ages women, but effects reverse after delivery

Eli Lilly to acquire Versanis in heated race for weight loss drugs

knowledge

comprehensive

hotspot

Guidelines to prevent youth baseball injuries need more muscle

This gene therapy has record $4.25 million price. It's saved children.

Trump demands the U.S. pay no more for drugs than other countries … again

With Wegovy coverage, Medicare patients may face high costs

Peter Hotez and the public health issue of online harassment

CRISPR technology availability, affordability needs to be expanded

Guidelines to prevent youth baseball injuries need more muscle

Diabetes management: Digital health tools fall short, study says

Hepatitis C has a cure — but many Americans still lack access to it

Blood tests recalled over risk of missed heart attack diagnosis

entertainment

Eli Lilly to acquire Versanis in heated race for weight loss drugs

Medicare Advantage insurers pressure Biden for bigger payments

Adam's Take: Intra

Texas board proposes rules on abortion law emergency exemption

Europe sees delivery challenges ahead on Alzheimer's therapies

Yancopoulos of Regeneron works to expand Dupixent success

leisure time

hotspot

explore

leisure time